StockData
Opus Genetics, Inc. logo

Opus Genetics, Inc. (IRD) stock

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.05+0.01 (+0.25%)

Close on Nov 17, 2026Market cap $336.94MP/E –Yield –

Opus Genetics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Opus Genetics's pe ratio was 2.1× on Jan 31, 2024.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Jan 31, 20242.1×−0.3
2023Dec 29, 20232.4×–

More Opus Genetics figures

See a number that looks wrong?